TELA Bio (TELA) hit with Nasdaq $1 bid-price deficiency, faces delisting risk

Rhea-AI Filing Summary

TELA Bio, Inc. reported that it received a notice from Nasdaq stating its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5450(a)(1) for the Nasdaq Global Market.

The stock will continue trading under the symbol “TELA” for now, and the notice has no immediate effect on the current listing. TELA Bio has until September 14, 2026 to regain compliance, which would occur if the closing bid price stays at or above $1.00 for at least 10 consecutive business days.

If compliance is not regained by that date, Nasdaq may grant an additional 180-day period if TELA transfers to the Nasdaq Capital Market and meets its other listing standards. Failure to regain compliance after these periods could lead to delisting, though the company would have the right to appeal. TELA Bio plans to monitor its share price and explore options to resolve the deficiency.

Positive

• None.

Negative

• Nasdaq minimum bid deficiency and delisting risk: TELA Bio’s stock has traded below the $1.00 Nasdaq Global Market bid requirement for 30 consecutive business days, starting a defined compliance period that could ultimately result in delisting if the price is not restored.

Insights

Equity markets and listing standards analyst

Nasdaq bid-price deficiency introduces clear delisting risk if not cured.

TELA Bio has fallen below Nasdaq’s $1.00 minimum bid for 30 consecutive business days, triggering a formal deficiency notice. The stock keeps trading on the Nasdaq Global Market, but the company is now on a defined compliance clock ending on September 14, 2026.

To regain compliance, the closing bid must reach at least $1.00 for 10 consecutive business days. If that fails, TELA might seek transfer to the Nasdaq Capital Market for a second 180‑day window, provided it meets other listing standards for publicly held shares.

If the price remains below the threshold after these periods, Nasdaq can move to delist, with TELA’s only recourse being an appeal to a hearings panel. The company indicates it will monitor its share price and consider options, but outcomes depend on future market trading and any actions it decides to take.

false 0001561921 0001561921 2026-03-17 2026-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

TELA Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39130		45-5320061
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania		19355
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		TELA		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 17, 2026, TELA Bio, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Global Market under the symbol “TELA” at this time.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until September 14, 2026, to regain compliance with Rule 5450(a)(1). If at any time before September 14, 2026, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance.

If the Company does not regain compliance with Rule 5450(a)(1) by September 14, 2026, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to transfer to The Nasdaq Capital Market and meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period. If the Staff concludes that the Company will not be able to cure the deficiency, or if the Company does not regain compliance with the minimum bid price requirement within such additional 180 calendar day compliance period, the Staff will provide written notification to the Company that the Company’s common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Hearings Panel (“Panel”). However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to Panel, such appeal would be successful.

The Company intends to actively monitor the closing bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with Rule 5450(a)(1). However, there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or that the Staff will grant the Company a further extension of time to regain compliance, if applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELA BIO, INC.
	By:	/s/ Antony Koblish
	Name:	Antony Koblish
	Title:	Chief Executive Officer and Director

Date: March 20, 2026

FAQ

What Nasdaq notification did TELA Bio (TELA) receive?

TELA Bio received a Nasdaq notice that its common stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Rule 5450(a)(1) for the Nasdaq Global Market.

Does the Nasdaq deficiency notice immediately affect TELA Bio stock trading?

The notice has no immediate effect on trading. TELA Bio’s common stock will continue to trade on the Nasdaq Global Market under the symbol “TELA” while the company works within the compliance periods.

How long does TELA Bio (TELA) have to regain Nasdaq bid-price compliance?

TELA Bio has until September 14, 2026 to regain compliance. It must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days within this initial 180‑day period.

Can TELA Bio receive more time beyond September 14, 2026 to meet Nasdaq rules?

If TELA Bio does not regain compliance by September 14, 2026, Nasdaq may grant an additional 180 days if the company transfers to the Nasdaq Capital Market and meets its other initial listing standards apart from the bid price.

What happens if TELA Bio still fails to meet the Nasdaq minimum bid requirement?

If TELA Bio remains noncompliant after all allowed periods, Nasdaq staff may notify the company that its common stock is subject to delisting. TELA Bio could then appeal the determination to a Nasdaq Hearings Panel, but success is not assured.

How does TELA Bio plan to address the Nasdaq bid-price deficiency?

TELA Bio states it will actively monitor the closing bid price of its common stock and consider available options to resolve the deficiency and regain compliance with Nasdaq Listing Rule 5450(a)(1), though no specific actions are detailed.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB